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Low-Dose Interleukin-2 for Treating Postautologous Transplant Cytogenetic Abnormality
Recurrency in a Case of Acute Myeloid Leukemia With Hyperdiploidy
To the Editor:
Adoptive immunotherapy and/or immunostimulation may be effec-
tive in treating early phases of leukemia relapsing after allogeneic
transplant. Donor lymphocyte infusion (DLI) is an established treat-
ment for cytogenetic relapse of chronic myeloid leukemia (CML) after
unmanipulated or T-cell–depleted bone marrow transplant (BMT)1;
favorable results have also been reported in a few cases of initial
posttransplant relapse of acute lymphoblastic leukemia (ALL) and acute
myeloid leukemia (AML).2 A graft-versus-leukemia (GVL) effect as
part of a manifest or occult DLI-elicited graft-versus-host disease
(GVHD) is thought to be the reason for these favorable results. For
patients who had received autologous transplant, attempts to elicit an
antineoplastic effect by immunostimulation have been made using in
vitro interleukin-2 (IL-2)–activated autologous lymphocytes and/or
IL-2 in vivo administration.3,4 We report on the successful use of
subcutaneous (sc) low-dose IL-2 in a patient suffering from AML with
recurrence of cytogenetic abnormalities after autografting.
A 56-year-old woman received diagnosis of AML French-American-
British (FAB) M1 in October 1995. Hemoglobin (Hb) level was 6.7
g/dL, platelet count 52 3 109/L, white blood cell count 4.3 3 109/L,
with 46% blast cells. A bone marrow (BM) aspirate showed 90%
medium-large sized leukemic blasts with immunophenotype CD131,
CD331, CD341, HLA-DR1. Cytogenetic analysis on 24-hour cultured
BM cells showed a hyperdiploid karyotype in 10 of 10 metaphases, with
8 near-triploid clones (chromosome count: 71,71,71,72,72,73,75,75),
having a common core XXX 11,12,13,14,15,16,17,17, 18,19,
110,111,112,113,114,115,115,116,120,121,122. The patient
was induced into complete remission (CR) with the EORTC-GIMEMA
AML-10 protocol, and received the scheduled consolidation course
with some delay for a pulmonary infection. In March 1996 stem cells
were mobilized by glycosylated recombinant human granulocyte colony-
stimulating factor (rhG-CSF) 10 µg/kg/d for 5 days and 2.2 3 106/kg
CD341 cells were collected from peripheral blood by four aphereses.
Autograft was performed in May 1996, after conditioning with BAVC
(carmustine 800 mg/m2 day 26, VP-16 150 mg/m2 days 25 to 23,
cytarabine 300 mg/m2 days 25 to 23, amsacrine 150 mg/m2 days 25 to
23). Hematological recovery was excellent and the patient was
discharged on day 120. Complete immunological reconstitution (nor-
mal natural killer [NK] cells and CD4/CD8 ratio) was documented 8
months after transplant. The patient remained in hematological and
cytogenetic (46 XX) CR until May 1997, when macrocytosis (mean
corpuscular volume [MCV] 105 fL) and moderate thrombocytopenia
(70 3 109/L) appeared. BM showed moderate trilinear dysplasia with-
out blast excess by morphology and flow cytometry; at that time NK
cells and CD4/CD8 ratio were decreased. Cytogenetic analysis revealed
a hyperdiploid karyotype (66-72 XXX) in 6 of 12 metaphases with the
same chromosomal abnormalities as at diagnosis. Because there were
no other signs of leukemia relapse, in July 1997 we started an
outpatient-based treatment with low-dose recombinant IL-2 (Proleukin;
Chiron, Emeryville, CA), 0.9 MU/m2 sc 4 days a week. Three months
later, the hyperdiploid clone was no longer detectable in BM (46 XX in
12 of 12 metaphases). In October 1998 she was still leukemia free, with
a normal karyotype (46 XX in 15 of 15 metaphases) and persistence of
dysplasia (MCV 108 fL, platelet count 69 3 109/L). Tolerance to IL-2
was excellent, with a normal quality of life; no eosinophilia was
observed. NK cells (especially the subset CD1221) increased, and
CD4/CD8 ratio rapidly returned to normal. Thus, even a prolonged
administration of low-dose IL-2 seems sufficient to produce a measur-
able immunostimulation. IL-2 treatment was stopped after 1 year.
IL-2 has been used in recent years as maintenance treatment of AML
patients, with discordant results5,6; the drug was usually ineffective in
relapsed or refractory AML patients, when the blast cell burden was high;
whereas encouraging results were observed in a few patients with low tumor
burden. High intravenous doses by continuous infusion were generally used,
causing severe side effects and poor compliance to the treatment. In a
controlled trial with short infusion of high-dose IL-2 for 2 months in AML
patients autotransplanted in first CR, no advantage was found on the
probability of relapse.7 We have used low doses of IL-2 for a prolonged
period of time without any side effects; this treatment was followed by
reversion of the recurrent cytogenetic abnormalities.
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Hyperdiploidy is reported in 10% to 20% of childhood ALL
and seems to be associated with good prognosis; it is a rare finding
in AML.8 No report on the association between hyperdiploidy and
dysplasia is present in the literature; in our patient, hyperdiploidy
and dysplasia were probably expressions of different phenomena.
Dysplasia was probably a late effect of the previous chemotherapy:
it was absent at diagnosis, and persisted at relapse even after dis-
appearance of hyperdiploidy. The absence of BM blastosis at
cytogenetic relapse is puzzling. We may surmise that in our patient
the hyperdiploid clone was not the actual leukemic clone, but
rather a preleukemic expansion of an (n-1) population from which
leukemia emerged. Even if this is the case, the immunological control
of the (n-1) clone may be of paramount importance in preventing
leukemia relapse. Finally, it is possible that different forms of
leukemia may have different sensitivity to an immunological
treatment, depending essentially on cell-surface alterations that
can be recognized by activated lymphocyte subsets. In this setting,
a hyperdiploid clone might be a better target for an immunological
attack, because cells may have an increased number of surface
molecules. Thus, it may well be that immunologic treatment of a
low-burden acute leukemia has selected indications, which are still to be
defined.
G. De Rosa
L. Pezzullo
C. Selleri
A.M. Raiola
L. Luciano
M. Picardi
B. Rotoli
Division of Hematology
Federico II University
Naples, Italy
REFERENCES
1. Kolb HJ, Holler E: Adoptive immunotherapy with donor lympho-
cyte transfusions. Curr Opin Oncol 9:139, 1997
2. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S: Induction
of graft-versus-host disease as immunotherapy of leukemia relapsing
after allogeneic transplantation: single-center experience of 32 adult
patients. Bone Marrow Transplant 20:129, 1997
3. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA,
Buckner CD, Fefer A: Immunotherapy with interleukin-2 with or
without lymphokine-activated killer cells after autologous bone marrow
transplantation for malignant lymphoma: a feasibility trial. Bone
Marrow Transplant 16:283, 1995
4. Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A,
Thompson JA, Buckner CD, Fefer A: Close simulation of acute
graft-versus-host disease by interleukin-2 administered after autologous
bone marrow transplantation for hematologic malignancy. Bone Mar-
row Transplant 17:351, 1996
5. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Gillio
Tos A, Mandelli F: Interleukin-2 may induce prolonged remissions in
advanced acute myelogenous leukemia. Blood 84:2158, 1994
6. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose
interleukin-2 on disease relapse after T-cell–depleted allogeneic bone
marrow transplantation. Blood 84:964, 1994
7. Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C,
Molina L, Nedellec G, Vernant JP, Legros M, Gabus R, Huguet F,
Brandely M, Hercend T, Olive D, Maraninchi D: The use of a sequential
high dose recombinant interleukin-2 regimen after autologous bone
marrow transplantation does not improve the disease free survival of
patients with acute leukemia transplanted in first complete remission.
Blood 87:2419, 1996
8. Clarke MR, Lynch EF, Cantis LC, Sherer ME, Shekhter-Levin S:
Near-tetraploidy in adult acute myelogenous leukemia. Cancer Genet
Cytogenet 86:107, 1996
Expression of AC133, a Novel Stem Cell Marker, on Human Leukemic Blasts Lacking CD342 Antigen
and on a Human CD341 Leukemic Cell Line: MUTZ-2
To the Editor:
A novel hematopoietic stem and progenitor cell marker, monoclonal
antibody (MoAb) AC133, was recently published by Miraglia et al1 and
Yin et al2 in the December 15, 1997 issue of Blood. AC133 recognizes
only CD34 bright and CD382 subsets of human progenitor cells
including colony-forming unit granulocyte macrophage (CFU-GM)
needed for short-term engraftment and probably the severe combined
immunodeficient (SCID) mouse repopulating cell.3 Investigators could
detect AC133 in a majority of CD341 cases of acute leukemia,
suggesting that it may be an early marker for human progenitor cells. In
contrast, they could not detect AC133 in the CD342 leukemic blasts of 1
patient with acute myelogenous leukemia (AML) or in any of 5 human
AML cell lines, although expression was found in 3 nonhematopoietic
cell lines of human origin.
We investigated several human cell lines by multiparameter immuno-
phenotyping using AC133-PE (Miltenyi, Bergisch Gladbach, Germany)
and CD34-Cy5, CD90-FITC (Immunotech, Marseille, France). We
found that a majority of cells of MUTZ-2 coexpressed CD34 and
AC133 (Fig 1). Mutz-2 is a cell line derived from AML and displays an
FAB:M2 morphology.4 This is the first known human hematopoietic
cell line expressing AC133, representing a possible additional tool for
experiments concerning the function of the AC133 receptor.
We also characterized expression of CD34 and AC133 in bone marrow
blasts from 10 patients withAML. None of the six patients with a pure CD34
negative blast population had detectable levels of AC1331 blasts. On the
other hand, we saw a 53-year-old male AML patient with blasts of FAB:M4
morphology and a high percentage of bone marrow infiltration (.90%
leukemic blasts) who had a mixed population of CD341 and CD342 blasts
(Fig 2). As expected, we found coexpression of CD34 and AC133 in 44% of
the blast population. Only a very small population of leukemic blasts was
AC1332 and CD341. Interestingly, we could find a significant blast
population (18%) in which expression of AC133 was not accompanied by
expression of CD34 or CD90 (Thy-1). This first report of a
CD342CD902AC1331 leukemic blast population could represent clonal
diversity of the blast population. On the other hand, it may suggest a possible
differentiation pathway, wherein CD342CD902AC1331 cells give rise to
CD341AC1331 cells. Alternatively, the CD341AC1331 blasts could be
progenitors of the CD342AC1331 cells seen in this patient. Therefore, our
finding of a CD342AC1331 blast population raises questions about the
significance of AC133 expression in AML. A more detailed investigation of
the role of AC133 in AML differentiation pathways needs to be done.
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